Summary
Intuitive Surgical, Inc. (ISRG) reported strong financial performance in its 2011 10-K filing, showcasing continued growth driven by the adoption of its da Vinci Surgical Systems. The company experienced a significant increase in total revenue, up 24% to $1.76 billion, propelled by both system sales and a robust increase in recurring revenue from instruments, accessories, and services. The installed base of da Vinci Surgical Systems grew to 2,132 units, supporting approximately 360,000 procedures performed globally during the year. The company highlights the strategic importance of recurring revenue, which represented 56% of total revenue in 2011, indicating a strong and growing installed base utilization. Key growth drivers included da Vinci Hysterectomy (dVH) and da Vinci Prostatectomy (dVP) procedures, alongside an increasing contribution from other surgical specialties like gynecology, cardiothoracic, and general surgery. Intuitive Surgical continues to invest heavily in research and development, focusing on product enhancements and new applications to further drive the adoption of minimally invasive surgery. Looking ahead, the company faces competitive pressures and the inherent risks associated with a novel technology, including market acceptance, regulatory hurdles, and potential economic downturns impacting capital expenditures. However, its expanding installed base, increasing procedure volumes, and focus on recurring revenue streams position it for continued growth. Investors should monitor the company's ability to maintain its technological leadership, navigate regulatory landscapes, and capitalize on the expanding adoption of robotic-assisted surgery across various medical specialties.
Financial Highlights
46 data points| Revenue | $1.76B |
| Cost of Revenue | $483.50M |
| Gross Profit | $1.27B |
| R&D Expenses | $140.20M |
| SG&A Expenses | $438.80M |
| Operating Expenses | $579.00M |
| Operating Income | $694.80M |
| Net Income | $495.10M |
| EPS (Basic) | $1.40 |
| EPS (Diluted) | $1.37 |
| Shares Outstanding (Basic) | 352.80M |
| Shares Outstanding (Diluted) | 361.80M |
Key Highlights
- 1Total revenue increased 24% to $1.76 billion in 2011, driven by a 29% increase in da Vinci procedures performed globally.
- 2Recurring revenue (instruments, accessories, and services) grew 30% to $979.5 million, constituting 56% of total revenue, indicating strong installed base utilization.
- 3The company sold 534 da Vinci Surgical Systems, an 18% increase from the previous year, expanding its installed base to 2,132 systems worldwide.
- 4Key procedures like da Vinci Hysterectomy (dVH) and da Vinci Prostatectomy (dVP) continue to be primary growth drivers, with other specialties showing increasing adoption.
- 5Research and development expenses increased 21% to $140.2 million, reflecting continued investment in product innovation and new applications.
- 6The company ended the year with substantial liquidity, holding $2.17 billion in cash, cash equivalents, and investments.
- 7Intuitive Surgical is actively repurchasing shares, with $568.2 million remaining under its authorized stock repurchase program as of December 31, 2011.